The Impact of Lung Function on Extra-Pulmonary Diseases and All-Cause Mortality in US Adult Population with and without COPD

Objective Spirometric lung function is usually used to evaluate respiratory health. However, the impact of lung function on extra-pulmonary diseases and all-cause mortality has not been fully elucidated, especially in people without chronic obstructive pulmonary disease (COPD). Patients and Methods Participants aged ≥20 and underwent spirometry test from the US National Health and Nutrition Examination Surveys (NHANES) 2007–2012 were analyzed in this study. Multivariate logistic and Cox regressions were used to evaluate the impact of forced expiratory volume in 1 second percent of predicted (FEV1% predicted) and forced vital capacity percent of predicted (FVC% predicted) on 14 extra-pulmonary diseases and all-cause morbidity after adjusting for multiple confounders. Results During 2007–2012, 1800 COPD patients and 11,437 non-COPD subjects were included. The prevalence of hypertension, diabetes mellitus (DM), dyslipidemia, metabolic syndrome (MS), congestive heart failure (CHF), coronary disease, stroke, chronic kidney disease (CKD), arthritis, cancer, underweight and osteoporosis in COPD patients was higher than that in the non-COPD population. After adjusting for confounders, the decrease of FEV1% predicted and FVC% predicted was related with higher odds of having hypertension, DM, obesity, MS, CHF, coronary disease and depression (OR > 1, P<0.05) in both the COPD and non-COPD populations. These 2 indices were also related with higher odds of dyslipidemia, CKD, arthritis and osteoporosis in the non-COPD population. The risk of stroke, anemia and cancer was not related with the decrease of lung function. In addition, the decrease of lung function was independent risk factors for the increase of all-cause mortality. These risks were gradually increased with the decrease of lung function. Conclusion The decrease of FEV1% predicted and FVC% predicted was related with higher risk of multiple extra-pulmonary diseases and all-cause mortality in both the COPD and non-COPD population.

[1]  Jessica L. Barrett,et al.  Projected U.S. State-Level Prevalence of Adult Obesity and Severe Obesity. , 2019, The New England journal of medicine.

[2]  Kevin McCarthy,et al.  Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement , 2019, American journal of respiratory and critical care medicine.

[3]  G. Parati,et al.  ACC/AHA Versus ESC/ESH on Hypertension Guidelines: JACC Guideline Comparison. , 2019, Journal of the American College of Cardiology.

[4]  I. Pavord,et al.  Measuring lung function in airways diseases: current and emerging techniques , 2019, Thorax.

[5]  Meilan K. Han,et al.  Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019 , 2019, European Respiratory Journal.

[6]  C. Liam,et al.  Clinical phenotypes of COPD and health-related quality of life: a cross-sectional study , 2019, International journal of chronic obstructive pulmonary disease.

[7]  S. Bozinovski,et al.  Pathobiological mechanisms underlying metabolic syndrome (MetS) in chronic obstructive pulmonary disease (COPD): clinical significance and therapeutic strategies , 2019, Pharmacology & Therapeutics.

[8]  A. Niles,et al.  Comparing Anxiety and Depression to Obesity and Smoking as Predictors of Major Medical Illnesses and Somatic Symptoms , 2019, Health psychology : official journal of the Division of Health Psychology, American Psychological Association.

[9]  International Association for the Study of Obesity , 2018, The Grants Register 2019.

[10]  Yeong Rae Joi,et al.  Racial differences in comorbidity profile among patients with chronic obstructive pulmonary disease , 2018, BMC Medicine.

[11]  C. Raherison,et al.  Comorbidities and COPD severity in a clinic-based cohort , 2018, BMC Pulmonary Medicine.

[12]  T. To,et al.  Health Services Burden of Undiagnosed and Overdiagnosed COPD , 2018, Chest.

[13]  S. Bojesen,et al.  AHRR hypomethylation, lung function, lung function decline and respiratory symptoms , 2018, European Respiratory Journal.

[14]  2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2018 , 2017, Diabetes Care.

[15]  K. Onishi.  Total management of chronic obstructive pulmonary disease (COPD) as an independent risk factor for cardiovascular disease. , 2017, Journal of cardiology.

[16]  Mahboob Rahman,et al.  Obstructive and Restrictive Lung Function Measures and CKD: National Health and Nutrition Examination Survey (NHANES) 2007-2012. , 2016, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[17]  S. K. Kim,et al.  Comorbidities in obstructive lung disease in Korea: data from the fourth and fifth Korean National Health and Nutrition Examination Survey , 2015, International journal of chronic obstructive pulmonary disease.

[18]  J. Yim,et al.  The relationship between chronic obstructive pulmonary disease and comorbidities: a cross-sectional study using data from KNHANES 2010-2012. , 2015, Respiratory medicine.

[19]  T. To,et al.  Mortality trends in women and men with COPD in Ontario, Canada, 1996–2012 , 2014, Thorax.

[20]  E. Ford,et al.  Lung function and metabolic syndrome: Findings of National Health and Nutrition Examination Survey 2007–2010 肺功能与代谢综合征：2007–2010全国健康与营养调查研究结果 , 2014, Journal of diabetes.

[21]  Yaw-Wen Chang,et al.  Relationship between Lung Function and Metabolic Syndrome , 2014, PloS one.

[22]  C. Irvin,et al.  Using lung function measurements to greater advantage in patients with lung disease: Which test and when? , 2014, Respirology.

[23]  E. Ford,et al.  Pulmonary function, chronic respiratory symptoms, and health-related quality of life among adults in the United States – National Health and Nutrition Examination Survey 2007–2010 , 2013, BMC Public Health.

[24]  A. Levin,et al.  Practice Guideline , 2020, Encyclopedia of Behavioral Medicine.

[25]  A. Looker.  Femur neck bone mineral density and fracture risk by age, sex, and race or Hispanic origin in older US adults from NHANES III , 2013, Archives of Osteoporosis.

[26]  C. Tantucci,et al.  Lung function decline in COPD , 2012, International journal of chronic obstructive pulmonary disease.

[27]  C. Bai,et al.  Tobacco smoking in China: Prevalence, disease burden, challenges and future strategies , 2011, Respirology.

[28]  Patrick D Mitchell,et al.  Hypoxemia in patients with COPD: cause, effects, and disease progression , 2011, International journal of chronic obstructive pulmonary disease.

[29]  S. Grundy,et al.  Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International As , 2009, Circulation.

[30]  C. Schmid,et al.  A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.

[31]  K. Rabe,et al.  Complex chronic comorbidities of COPD , 2008, European Respiratory Journal.

[32]  K. Larsson,et al.  COPD diagnosis related to different guidelines and spirometry techniques , 2007, Respiratory research.

[33]  A. Bhunia,et al.  Hypoxia and chronic lung disease , 2007, Journal of Molecular Medicine.

[34]  R. Spitzer,et al.  The PHQ-9 , 2001, Journal of General Internal Medicine.

[35]  Y. Jang,et al.  Standards of Medical Care in Diabetes-2010 by the American Diabetes Association: Prevention and Management of Cardiovascular Disease , 2010 .

[36]  A. Agustí.  Systemic effects of chronic obstructive pulmonary disease. , 2001, Novartis Foundation symposium.

[37]  J L Hankinson,et al.  Spirometric reference values from a sample of the general U.S. population. , 1999, American journal of respiratory and critical care medicine.